Tau Protein Alzheimer's Disease

The" Big Bang" of Alzheimer's disease: Breaking through trial reveals development of the disease

Significant new research conducted by UT Southwestern has uncovered the early point in a neuro-degenerative path leading to the onset of neurological dementias. Alzheimer' s disease, and it is expected that the work will result in new therapies and new ways to recognise the disease before the main signs take effect.

" A lot of advanced Alzheimer's research is focused on a protein specifically named Alzheimer' s disease and the aggregation of this protein is believed to be the main cause of disease manifestations. The new research is focused on another protein known as dew. The tau protein was found to build aberrant clots in the brains, named neurofibrillar confusions, which can build up and destroy each other.

A number of scientists assume that this is the main cause of Alzheimer's disease. Up to now it was not known how and when these tau-protein began to become felted in the brains. In the past it was thought that dew protein isolates did not have a very damaging form until they began to clump with other dew protein isolates.

However, new research has shown that a poisonous tau protein is in fact falsely folding and exposes parts that are normally inside it before it begins to agglomerate. It' s these exponentially bound parts of the protein that allow accumulation and create the greater intoxication. "That is one way to look back at the beginning of the disease progression.

This brings us back to a very discrete point where we see the first molecule alteration leading to neurodedegeneration in Alzheimer's disease. The first step will be to develop a basic diagnostics test to identify indications of this anomalous tau protein, either by a test of human tau or less ideal by a spine test.

Alzheimer' s disease can be diagnosed before the most important deteriorative as well as severe dysfunction occurs if these tau protein toxins can be readily identified. A second research path resulting from this great finding is the investigation of prophylactic pharmaceutical treatment that could disrupt the tau accumulation processes. Scientists point to a new medication named tableamidis, an interesting example of a similar protein stabilizing medication that can clot and cause unwanted manifestations.

Tableamidis was developed to retard the impairments of neural functions by the poisonous accumulation of a normally innocuous protein named transsthyretin and is currently authorised in both Europe and Japan. The FDA has, however, requested further evidence before the medicine is licensed in the US.

With this early change detected in the form of dew molecule, scientists can now concentrate more efficiently on target compounds to block the toxins at this state. "Hunting is designed to be based on this findings and to provide treatments that block the neurodegenerative processes where they begin," says Diamond.

"Alzheimer' s disease could be significantly decreased if it works.